common.skip_to_content
USE CODE MUNCHMAKERS FOR 10% OFF YOUR FIRST ORDER (650) 955-1836 Open now · until 5pm PT | REQUEST A CALLBACK
USE MUNCHMAKERS FOR 10% OFF YOUR FIRST ORDER

Charlotte's Web Opposes Section 781, Calls for Targeted Hemp Rules

CBD company backs bipartisan framework to ban delta-8 while preserving therapeutic products

Charlotte's Web, one of the nation's largest CBD manufacturers, is backing a bipartisan congressional proposal to replace sweeping hemp restrictions in Section 781 with more targeted regulations that would ban synthetic intoxicants while preserving access to therapeutic hemp products.

The company called on Congress to reject Section 781's broad approach in favor of standards that would specifically eliminate synthetic and restricted intoxicating products like delta-8 THC while maintaining consumer access to non-intoxicating hemp derivatives. Charlotte's Web has built its business on CBD products marketed for therapeutic use, particularly its namesake strain developed for pediatric epilepsy patients.

Section 781, introduced in the previous Congress, proposed significant restrictions on hemp-derived products that industry advocates warned would effectively eliminate most CBD products from the market. The provision never advanced, but similar language has resurfaced in recent legislative discussions as lawmakers grapple with the proliferation of intoxicating hemp products in gas stations and convenience stores.

The Hemp Intoxicant Problem

The market for intoxicating hemp products has exploded since the 2018 Farm Bill legalized hemp production. Delta-8 THC, delta-10 THC, and other semi-synthetic cannabinoids derived from CBD have created a largely unregulated market for products that produce psychoactive effects similar to marijuana. These products are sold in states where cannabis remains illegal, creating what critics call a regulatory loophole.

Charlotte's Web argues that Congress can address this issue without eliminating therapeutic hemp products that contain minimal or no intoxicating compounds. The company supports age restrictions, child-resistant packaging requirements, and bans on synthetic cannabinoids while opposing blanket restrictions that would affect products with established safety profiles.

The bipartisan framework Charlotte's Web is backing would establish clear definitions separating therapeutic hemp products from intoxicating ones. The company has not disclosed which specific members of Congress are involved in developing the proposal, though multiple bipartisan bills addressing hemp regulation have been introduced in recent months.

Industry Split

The hemp industry remains divided on how to address federal regulation. Some companies producing intoxicating hemp products argue that all hemp derivatives should remain legal under the 2018 Farm Bill's language. Others, particularly established CBD brands, support stricter rules that would differentiate their products from intoxicants.

Charlotte's Web's position reflects its market focus on wellness products rather than intoxicating ones. The company went public in 2018 and has positioned itself as a premium CBD brand emphasizing quality control and third-party testing. Its support for restrictions on delta-8 and similar products could be seen as protecting its market position, though the company frames it as a consumer safety issue.

The CBD market has struggled since its initial post-Farm Bill boom, with sales plateauing and major retailers remaining hesitant to carry hemp products without clear FDA guidance. Charlotte's Web reported declining revenues in recent quarters as the broader CBD market contracted.

What Happens Next

Congress has yet to advance comprehensive hemp regulation despite multiple proposals. The FDA has also failed to establish a regulatory framework for CBD in food and dietary supplements, leaving the hemp industry in legal limbo more than six years after the Farm Bill passed.

Any legislative solution will need to balance competing interests: state regulators seeking clarity, law enforcement concerned about intoxicating products, established hemp companies wanting to preserve their markets, and newer entrants in the delta-8 space. Charlotte's Web is betting that Congress will ultimately draw a line between therapeutic and intoxicating hemp products rather than imposing broad restrictions.

The company's advocacy could influence how major hemp producers approach federal regulation. If other established CBD brands align with Charlotte's Web's position, it could create industry momentum for targeted restrictions rather than sweeping bans.


This article is based on original reporting by www.cannabisbusinesstimes.com.

More from David Okonkwo